immunotherapy / IL10 Cancer Research Results

immuno, immunotherapy: Click to Expand ⟱

Features:

Immunotherapy is not one drug class. It includes:
-Immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4)
-CAR-T therapies
-Monoclonal antibodies
-Cytokine therapies (IL-2, IFN-α)
-Cancer vaccines
-Bispecific T-cell engagers

PD-1 blockade antibody therapy is one of the cornerstone approaches in modern cancer immunotherapy.
Under normal physiological conditions, when PD-1 binds to its ligands (PD-L1 or PD-L2) on other cells, it functions as a "checkpoint" to reduce overly active T cell responses and prevent autoimmunity.
PD-1 blockade therapies involve monoclonal antibodies that target either PD-1 or its ligand PD-L1.
• By blocking the interaction between PD-1 and its ligands, these antibodies effectively release the "brakes" on T cells.
• The re-activated T cells can then recognize and destroy cancer cells more efficiently.

Immunotherapy Class	Example Agents	Primary Target	Core Mechanism	Interaction Considerations	Net Effect
PD-1 inhibitors	Nivolumab, Pembrolizumab	PD-1 receptor on T cells	Blocks inhibitory PD-1 signaling → restores cytotoxic T-cell activity	High-dose steroids or strong immunosuppressants may blunt effect; autoimmune risk	↑ Anti-tumor immune activation
PD-L1 inhibitors	Atezolizumab, Durvalumab	PD-L1 on tumor/immune cells	Prevents PD-L1 from engaging PD-1 → enhances T-cell response	Similar immune-related adverse event (irAE) profile as PD-1 inhibitors	↑ Immune activation
CTLA-4 inhibitors	Ipilimumab	CTLA-4 checkpoint	Enhances early T-cell priming in lymph nodes	Higher autoimmune toxicity risk vs PD-1 class	↑ T-cell priming
CAR-T therapy	CD19 CAR-T products	Tumor antigen (e.g., CD19)	Genetically engineered T cells directly target tumor cells	Risk of cytokine release syndrome (CRS) and neurotoxicity	Direct immune-mediated tumor killing
Monoclonal antibodies (non-checkpoint)	Trastuzumab, Rituximab	Specific tumor antigens	Antibody-dependent cellular cytotoxicity (ADCC) or receptor blockade	Combination with chemo common; immune activation depends on Fc engagement	Targeted immune-mediated killing
Cytokine therapy	IL-2, IFN-α	Immune activation pathways	Stimulates T-cell and NK cell proliferation	High systemic toxicity; rarely used now vs checkpoint inhibitors	Broad immune stimulation
Cancer vaccines	mRNA or peptide-based	Tumor antigens	Induces tumor-specific immune memory	Often combined with checkpoint blockade	Adaptive immune priming
Bispecific T-cell engagers	Blinatumomab	CD3 + tumor antigen	Bridges T cells directly to tumor cells	CRS risk; continuous infusion in some protocols	Direct T-cell redirection

IL10, Interleukin-10: Click to Expand ⟱

Source:

Type:

IL-10 is a multifaceted immune-suppressive cytokine and possesses immune-regulatory and angiogenic functions.
It primarily acts as an anti-inflammatory cytokine, protecting the body from an uncontrolled immune response, mostly through the Jak1/Tyk2 and STAT3 signaling pathway. On the other hand, IL-10 can also have immunostimulating functions under certain conditions.
The role of IL-10 in tumor pathogenesis is currently highly controversial, with some findings showing that IL-10 promotes tumor development and angiogenesis, while others supporting that it inhibits tumor growth and metastasis.

IL-10 is often expressed in various cancers, including breast cancer, colorectal cancer, melanoma, and lymphoma. Its expression can vary significantly depending on the tumor type and the immune context.
Elevated levels of IL-10 are frequently associated with the presence of tumor-infiltrating immune cells, particularly Tregs and M2 macrophages.

Scientific Papers found: Click to Expand⟱

1041-

Lyco,

immuno,

Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells

in-vivo,

Lung,

mice

TumVol↓, TumW↓, eff↑, IL1↑, IFN-γ↑, IL4↓, IL10↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Immune & Inflammatory Signaling ⓘ

IFN-γ↑, 1, IL1↑, 1, IL10↓, 1, IL4↓, 1,

Drug Metabolism & Resistance ⓘ

eff↑, 1,

Functional Outcomes ⓘ

TumVol↓, 1, TumW↓, 1,
Total Targets: 7

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: IL10, Interleukin-10

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells